PEPG Live signals | Maximize Profits with Getagraph.com

SELL 102403 min ago

@ $14.13

Issued: 14 Feb 2024 @ 09:30

Return: -20.59%

Previous signal: Feb 12 - 14:52

Previous signal: Buy

Return: 10.05 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 13:09):

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases...

Stats
Today's Volume	14 088.00
Average Volume	139 464
Market Cap	363.41M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.720 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.40
ATR14	$0.154 (1.37%)

Insider Trading

Date	Person	Action	Amount	type
2022-05-10	Oxford Science Enterprises Plc	Buy	879 970	Common Stock
2024-03-01	Svenstrup Niels	Buy	83 000	Stock Option (Right to Buy)
2024-03-01	Mcarthur James G	Buy	300 000	Stock Option (Right to Buy)
2024-03-01	Donnelly Noel	Buy	144 000	Stock Option (Right to Buy)
2024-03-01	Mellion Michelle L	Buy	83 000	Stock Option (Right to Buy)

INSIDER POWER
85.92
Last 93 transactions
Buy: 15 622 342 \| Sell: 5 738 999

Volume Correlation

Long: -0.15 (neutral)

Short: 0.59 (weak)

Signal:(45.805) Neutral

PepGen Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

PepGen Inc. Correlation - Currency/Commodity

-0.61
( weak negative )

0.00
( neutral )

-0.44
( neutral )

-0.04
( neutral )

0.42
( neutral )

PepGen Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.18M (0.00 %)
EPS:	$-3.30

Q4	2023
Revenue:	$1.66M
Gross Profit:	$1.31M (78.67 %)
EPS:	$-0.820

Q3	2023
Revenue:	$0
Gross Profit:	$-349 000 (0.00 %)
EPS:	$-0.980

Q2	2023
Revenue:	$0
Gross Profit:	$-331 000 (0.00 %)
EPS:	$-0.820

Financial Reports:

No articles found.

PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.